TABLE 3. Characteristics of currently and recently pregnant persons* with mpox (N = 23) — United States, May 11–November 7, 2022.
| Characteristic | No. (%)† |
|---|---|
| Currently pregnant |
21 (91.3) |
| Recently pregnant |
2 (8.7) |
|
Pregnancy trimester when Monkeypox virus infection occurred (10)
| |
| First |
3 (30.0) |
| Second |
4 (40.0) |
| Third |
3 (30.0) |
| Missing |
11 |
|
Sign or symptom
§
| |
| Fever |
6 (26.1) |
| Rash |
23 (100.0) |
| Genital or breast lesions |
4 (17.4) |
| Myalgia |
2 (8.7) |
| Pruritis |
6 (26.1) |
| Lymphadenopathy |
3 (13.0) |
|
Disease severity
| |
|
Hospitalized
| |
| Yes |
4 (17.4) |
| No |
19 (82.6) |
| Admitted to ICU |
0 (—) |
|
Mpox-directed therapy
¶
| |
| Tecovirimat (oral or IV) |
11 (47.8) |
| VIGIV |
0 (—) |
|
Postexposure prophylaxis
| |
| Received JYNNEOS | 0 (—) |
Abbreviations: ICU = intensive care unit; IV = intravenous; mpox = monkeypox; VIGIV= vaccinia immune globulin intravenous.
* Recently pregnant persons had confirmed or probable Monkeypox virus infection within 21 days of delivery.
† Percentages calculated among nonmissing values.
§ Signs and symptoms are not mutually exclusive.
¶ Two women who received tecovirimat also received other treatments (e.g., acyclovir or antibiotics).